Brief: Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy
18/08/2025 15:25
Aug 18 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O: ULTRAGENYX INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR DTX401 AAV GENE THERAPY FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA) ULTRAGENYX PHARMACEUTICAL INC - PLANS TO COMPLETE FULL BLA SUBMISSION IN Q4 2025 Source text: ID:nGNX2hr10r Further company coverage: RARE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx